On Oct 30, major Wall Street analysts update their ratings for $Stryker Corp (SYK.US)$, with price targets ranging from $370 to $420.
BofA Securities analyst Travis Steed maintains with a buy rating, and sets the target price at $400.
UBS analyst Danielle Antalffy maintains with a hold rating, and adjusts the target price from $351 to $370.
Wells Fargo analyst Larry Biegelsen maintains with a buy rating, and adjusts the target price from $381 to $405.
Jefferies analyst Matthew Taylor maintains with a buy rating, and adjusts the target price from $400 to $415.
Baird analyst Jeff Johnson maintains with a buy rating, and adjusts the target price from $378 to $405.
Furthermore, according to the comprehensive report, the opinions of $Stryker Corp (SYK.US)$'s main analysts recently are as follows:
Stryker's recent financial results exceeded expectations, with the prospect of growth by 2025 being attributed to the launch of new products and the anticipated contributions from mergers and acquisitions, which include about seven deals in the pipeline. Additionally, the continued expansion of the Mako platform, particularly with two new indications, is expected to bolster growth. The analyst's position remains neutral pending stronger confidence in sales and earnings per share outperformance relative to consensus estimates.
Stryker reported robust and diverse results for Q3, with revenue surpassing expectations. Although the implied organic growth rate is somewhat below the company's historical trend for a seasonally strong quarter, Stryker anticipates maintaining healthy procedural dynamics, favorable pricing, and product growth drivers to uphold its premium growth trajectory.
The recent quarter showcased another strong performance, with global organic growth returning to double-digit figures. This marks a significant milestone as orthopedic pricing has seen a positive turn for the first time in ten years, and earnings per share have been expanding at or above the mid-teen rate.
Stryker's third-quarter results presented a positive surprise in sales, particularly led by its MedSurg division. The projection for the fourth quarter is deemed to be on the cautious side, while the company's strong business momentum is expected to carry on through 2025.
Here are the latest investment ratings and price targets for $Stryker Corp (SYK.US)$ from 12 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間10月30日，多家華爾街大行更新了$史賽克 (SYK.US)$的評級，目標價介於370美元至420美元。
美銀證券分析師Travis Steed維持買入評級，目標價400美元。
瑞士銀行分析師Danielle Antalffy維持持有評級，並將目標價從351美元上調至370美元。
富國集團分析師Larry Biegelsen維持買入評級，並將目標價從381美元上調至405美元。
富瑞集團分析師Matthew Taylor維持買入評級，並將目標價從400美元上調至415美元。
貝雅分析師Jeff Johnson維持買入評級，並將目標價從378美元上調至405美元。
此外，綜合報道，$史賽克 (SYK.US)$近期主要分析師觀點如下：
Stryker最近的財務業績超出預期，到2025年的增長前景歸因於新產品的推出以及併購所帶來的預期貢獻，其中包括大約七筆即將完成的交易。此外，Mako平台的持續擴張，尤其是在兩個新適應症方面，預計將提振增長。分析師的立場仍保持中立，等待更強的銷售和每股盈利的信心超過共識預期。
Stryker報告了第三季度強勁而多樣化的業績，營業收入超出預期。儘管暗示的有機增長率略低於公司歷史強勁季度的趨勢，但Stryker預計將保持健康的程序動態、有利的定價和產品增長驅動因素，以維持其優質增長軌跡。
最近一個季度展示了另一次強勁表現，全球有機增長率回到兩位數。這標誌着骨科定價在十年來首次呈現積極轉機，每股收益已經以或高於中青少年增長率擴張。
Stryker第三季度的業績呈現出銷售的積極意外，特別是其MedSurg部門領漲。第四季度的預測被認爲較爲謹慎，而公司強勁的業務勢頭預計將持續至2025年。
以下爲今日12位分析師對$史賽克 (SYK.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
